PETHEMA Foundation

• NCT07507760

  Phase 2, Recruiting, 50 people, 2 Apr 2026

• Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  Phase 3, Recruiting, 376 people, 18 Mar 2026

• NCT07045909

  Phase 2, Recruiting, 30 people, 1 Jul 2025

• NCT05849610

  Phase 2, Active, not recruiting, 30 people, 9 May 2023

• NCT05558319

  Phase 3, Recruiting, 480 people, 28 Sept 2022

• NCT05527340

  Phase 2, Active, not recruiting, 140 people, 2 Sept 2022

• NCT05060627

  Phase 1/2, Active, not recruiting, 60 people, 29 Sept 2021

• NCT05049473

  Phase 2, Status unknown, 100 people, 20 Sept 2021

• NCT04802356

  Phase 2, Active, not recruiting, 50 people, 17 Mar 2021

• NCT04687761

  Phase 1/2, Completed, 113 people, 29 Dec 2020

• NCT03742297

  Phase 3, Active, not recruiting, 462 people, 15 Nov 2018

• NCT03589222

  Phase 2, Active, not recruiting, 62 people, 17 Jul 2018

• NCT03336073

  Phase 2, Status unknown, 199 people, 8 Nov 2017

• NCT03280160

  Phase 2, Status unknown, 84 people, 12 Sept 2017

• NCT03023527

  Phase 1, Terminated, 6 people, 18 Jan 2017

• NCT02776605

  Phase 2, Status unknown, 30 people, 18 May 2016

• NCT02575144

  Phase 3, Status unknown, 286 people, 14 Oct 2015

• NCT02415413

  Phase 2, Active, not recruiting, 90 people, 14 Apr 2015

• NCT02406144

  Phase 3, Completed, 316 people, 2 Apr 2015

• NCT02384083

  Phase 1/2, Completed, 47 people, 10 Mar 2015

Sources: clinicaltrials.gov